Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Lowered by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 16.8% during the fourth quarter, Holdings Channel reports. The firm owned 6,652 shares of the biotechnology company’s stock after selling 1,340 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Sarepta Therapeutics were worth $641,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in SRPT. Vanguard Group Inc. raised its holdings in shares of Sarepta Therapeutics by 0.5% during the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock valued at $1,039,212,000 after acquiring an additional 41,465 shares during the period. Picton Mahoney Asset Management acquired a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $2,576,000. WCM Investment Management LLC acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $600,000. Capula Management Ltd acquired a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $1,409,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Sarepta Therapeutics by 351.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company’s stock valued at $1,044,000 after acquiring an additional 8,427 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Insider Activity at Sarepta Therapeutics

In other news, insider Bilal Arif sold 2,000 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 in the last ninety days. 7.40% of the stock is currently owned by insiders.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $127.39 on Friday. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $11.96 billion, a price-to-earnings ratio of -20.82 and a beta of 0.94. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $159.89. The firm has a 50 day moving average of $126.22 and a two-hundred day moving average of $110.43.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. During the same period in the previous year, the firm posted ($1.24) earnings per share. The company’s revenue for the quarter was up 53.6% compared to the same quarter last year. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Evercore ISI boosted their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price target on the stock. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Citigroup boosted their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.38.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.